RT Journal Article T1 A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema. A1 Doña, Inmaculada A1 Torres, Maria Jose K1 Vasodilation K1 Chronic Disease K1 Angioedemas, Hereditary K1 Quality of Life K1 Bradykinin K1 Cost of Illness K1 Capillary Permeability K1 Andalusian Center for Nanomedicine and Biotechnology-BIONAND AB Hereditary angioedema (HAE) is a rare inherited chronic disease characterized by unpredictable recurrent attacks of cutaneous and submucosal swelling potentially involving airways, frequently upper ones, and compromising patient's life. This implies a serious health problem with significant disease burden and reduced life quality. This disease presents a great clinical variability and different endotypes, hampering diagnosis and requiring a personalized treatment. The primary mediator of swelling in most phenotypes is bradykinin, which increases vasodilation and vascular permeability by binding to the bradykinin B2 receptor. PB John Wiley and Sons YR 2021 FD 2021-02-23 LK http://hdl.handle.net/10668/17250 UL http://hdl.handle.net/10668/17250 LA en NO Doña I, Torres MJ. A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema. Allergy. 2021 Jun;76(6):1619-1620 DS RISalud RD Apr 6, 2025